Related Experiment Video
Updated: Jul 22, 2025

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review
Meity Ardiana1,2, Asiyah Nurul Fadila1,2, Zakirah Zuhra1,2
1Department of Cardiology and Vascular Medicine, Dr.Soetomo General Hospital, Surabaya, Indonesia.
Abstract:
At present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for CVDs and risk factors management. However, data are primarily in an early stage. A systematic review was carried out using literature from several databases (Pubmed, Cochrane, Scopus, and DOAJR) following the PRISMA guidelines. Of the 64 articles reviewed, 39 papers were included in this review with three main types of RNAs: aptamers, antisense oligonucleotides (ASOs), and small-interfering RNA (siRNA). All studies were human clinical trials. RNA-based therapies were demonstrated to be efficacious in treating various CVDs and controlling cardiovascular risk factors. They are generally safe and well-tolerated. However, data are still in the early stage and warrant further investigation.
More Related Videos
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease I: Introduction
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

